Combination of amyloid and FDG PET for the prediction of short-term conversion from MCI to Alzheimer´s disease in the clinical practice
Purpose Amnestic mild cognitive impairment (aMCI) is considered a precursor to Alzheimer’s disease (AD). Since cerebral amyloid aggregation and neurodegeneration can be detected at an early stage, it can serve as a diagnostic aid. This study aimed to determine the predictive value of Amyloid-PET and...
| Autores: | , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2025 |
| País: | España |
| Institución: | Consejo Superior de Investigaciones Científicas (CSIC) |
| Repositorio: | Dadun. Depósito Académico Digital de la Universidad de Navarra |
| Idioma: | inglés |
| OAI Identifier: | oai:dadun.unav.edu:10171/120959 |
| Acceso en línea: | https://hdl.handle.net/10171/120959 |
| Access Level: | acceso abierto |
| Palabra clave: | Amnestic mild cognitive impairment (aMCI) Alzheimer’s disease (AD) Short-term conversion AmyloidPET FDG-PET |
| Sumario: | Purpose Amnestic mild cognitive impairment (aMCI) is considered a precursor to Alzheimer’s disease (AD). Since cerebral amyloid aggregation and neurodegeneration can be detected at an early stage, it can serve as a diagnostic aid. This study aimed to determine the predictive value of Amyloid-PET and FDG-PET in determining progression to AD among patients with aMCI. Methods This study recruited 145 patients with aMCI from October 2013 to March 2021. The patients were classified into four groups based on whether Amyloid-PET (A) and FDG-PET (N) were positive (+) or negative (-). The patients were then clinically followed to establish progression to dementia due to AD. Results Amyloid-PET demonstrated high sensitivity (100% in year 1, 94.67% in year 4) and a high negative predictive value (100% in year 1, 88.24% in year 4). FDG-PET exhibited a high negative predictive value initially (94.59% in year 1), and during follow-up, both specificity (85%) and positive predictive value (88%) increased. The conversion from aMCI to AD had a global mean time of 39.95 months. However, progression to AD was slower in amyloid-negative patients versus amyloid-positive patients (75.07 [CI 56.54–81] vs. 32.59 months [CI 20.56–40.74] months). Taking both tests together, the time to conversion was faster in A+/N+versus A+/N- patients (27.79 [CI 20.40–33.21] vs. 37.38 [CI 20.73–48.26] months). Conclusions Among patients with aMCI, those with a positive Amyloid-PET and an AD pattern on FDG-PET progressed to dementia significantly earlier versus those with a positive Amyloid-PET only. Using both biomarkers during the initial diagnosis enhances the prediction of short-term conversion. Clinical trial number Not applicable. It is not a clinical trial |
|---|